CClinicalTrials.gg
TerminatedNCT04598152MDMNUpdated Jan 4, 2022Results posted

Modulating Default Mode Network Function: A Transcranial Direct Current Stimulation (TDCS) Pilot Study

An interventional study of TDCS - transcranial direct current stimulation in Depression, Anxiety, sponsored by Jay Fournier. Terminated at 1 site in United States. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2022-01-04.

Sponsored by Jay Fournier · Not applicable, Interventional, and Other

Why this study was terminated
Covid restrictions prevented continuation during the funding window

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Oct 2018, registered Oct 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 30 Years
Sex
All
01

Study summary

The primary purpose of this research is to gather scientific information about how different people's brains work when they look at different types of pictures. This will help to improve the investigators' understanding of the way the brain works for people who are depressed or anxious, and this knowledge could help lead to better diagnosis and treatment.

Read the detailed description

In this study the investigators are examining the effects of weak electrical stimulation on brain activity as measured by functional magnetic resonance imaging (fMRI). MRI is a widely used method to obtain high resolution brain pictures that are routinely used for diagnostic and clinical purposes. The electrical stimulation is applied on the scalp with a non-FDA approved method called tDCS (transcranial Direct Current Stimulation), typically equivalent to what a 6V battery would produce (and up to no more than 15V). To compare, an AA battery delivers current at 1.5 volt. While almost unnoticeable to the participants, these currents can still temporarily affect brain activity without causing adverse effects. This stimulation would be applied while the participants are in the MRI scanner so that the brain activity can be measured. The participants will have the opportunity to have a test session with the stimulation outside the scanner to get familiar with it.

02

Conditions studied

  • Depression, Anxiety

Browse trials for

03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 4 is below the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Jay Fournier is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Between 18-30years old
  2. Score > 10 on the QIDS or > 60 on the PROMIS-A
  3. We will use a flexible extreme groups recruitment strategy to ensure an adequate distribution of ESC scores. We will ensure that at least 62% of the sample will be composed of those scoring .5 SD above or below the mean, as measured by the NEO-PI-R. This value corresponds to the expected values assuming a normal distribution of the trait.
  4. Normal or corrected to normal vision with contact lenses
  5. Able to provide informed consent in English
  6. Right-handed (Annett criteria)

Exclusion criteria

Exclusion Criteria:

  1. Have a history of head trauma with loss of consciousness.
  2. Have a systemic medical illness that may impact fMRI measures of cerebral blood flow.
  3. Meet standard exclusion criteria for fMRI scanning (e.g. claustrophobia, cardiac pacemakers, neural pacemakers, surgically implanted metal devices, cochlear implants, metal braces, or other MRI non-safe metal objects in the body).
  4. Are pregnant (self report and tested for as part of any scan by the scanning center and not this protocol)
  5. Not native English speaking or not fluent
  6. Premorbid NAART IQ estimate\<85;
  7. Visual disturbance (worse than 20/40 Snellen visual acuity) that is not corrected
  8. If have visual disturbance, only access to correction with glasses (i.e., no access to contact lenses).
  9. Left/mixed handedness (Annett criteria), to ensure a uniform hemispheric dominance for interpretation of neuroimaging data
  10. Active suicidal ideation in need of immediate treatment
  11. Scoring below the cutoffs on both the QIDS and the PROMIS-A
  12. History of alcohol/substance use disorder (including nicotine) and/or illicit substance use (except cannabis) over the last 3 months, determined by the MINI. Lifetime/present cannabis use (non-disordered levels) will be allowed, given its common usage in individuals in this age range.
  13. Current or past psychotic-spectrum disorder
  14. History of seizures
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Transcranial Direct Current Stimulation during fMRI

    Each subject will undergo transcranial direct current stimulation twice while completing a task in the functional magnetic resonance imaging scanner.

    Device: TDCS - transcranial direct current stimulation

Interventions

  • DeviceTDCS - transcranial direct current stimulation

    TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.

06

What researchers measure

Primary outcomes

  1. Blood Oxygen Level Dependent (BOLD) Response in the Precuneus During an Emotion Regulation Task Completed During fMRI Scanning.

    The investigators will determine the effects of TDCS on BOLD response in the precuneus/posterior cingulate gyrus. The BOLD signal is a measure of regional blood flow in the brain and is used as a proxy for neural activity in specific brain regions. Values below represent pre-post change in BOLD response to the emotion regulation task that participants complete during fMRI scanning. We hypothesize that tDCS applied to the target used in this study will decrease BOLD signal (lower values) during critical components of this task, normalizing function in this region.

    Time frame: 1 week (between baseline and repeat scanning)

Secondary outcomes

  1. The Percentage of Patients Who Reported a Side Effect in the Active tDCS Condition But Not the Sham tDCS Condition

    Potential side effects (e.g., headaches, dizziness, uncomfortable sensations, etc...) will be assessed after each tDCS and sham-tDCS administration. Side effects were assessed using a standardized form. Count below represents the number of participants who reported a mild or moderate side effect during active tDCS but not sham tDCS.

    Time frame: 30 minutes to 1 hour (the period during which the tDCS device was worn) on each of two scan days

07

Results

Posted Jan 4, 2022
Limitations and caveats
This study was closed due to Covid 19 restrictions. Only 3 people completed the protocol. No conclusions should be drawn from the results reported. Because of the low sample size, no statistical analyses were undertaken.

Participant flow

Participant flow — Overall Study
MilestoneSham Transcranial Direct Current Stimulation (tDCS) During fMRI Followed by Active tDCS During fMRIActiveTranscranial Direct Current Stimulation (tDCS) During fMRI Followed by Sham tDCS During fMRI
Started31
Completed30
Not completed01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryBlood Oxygen Level Dependent (BOLD) Response in the Precuneus During an Emotion Regulation Task Completed During fMRI Scanning.

The investigators will determine the effects of TDCS on BOLD response in the precuneus/posterior cingulate gyrus. The BOLD signal is a measure of regional blood flow in the brain and is used as a proxy for neural activity in specific brain regions. Values below represent pre-post change in BOLD response to the emotion regulation task that participants complete during fMRI scanning. We hypothesize that tDCS applied to the target used in this study will decrease BOLD signal (lower values) during critical components of this task, normalizing function in this region.

Time frame:
1 week (between baseline and repeat scanning)
Reported as:
Mean · arbitrary units
Blood Oxygen Level Dependent (BOLD) Response in the Precuneus During an Emotion Regulation Task Completed During fMRI Scanning.
arbitrary unitsActive vs Sham Transcranial Direct Current Stimulation During fMRI
Blood Oxygen Level Dependent (BOLD) Response in the Precuneus During an Emotion Regulation Task Completed During fMRI Scanning.-.09 ± .36
SecondaryThe Percentage of Patients Who Reported a Side Effect in the Active tDCS Condition But Not the Sham tDCS Condition

Potential side effects (e.g., headaches, dizziness, uncomfortable sensations, etc...) will be assessed after each tDCS and sham-tDCS administration. Side effects were assessed using a standardized form. Count below represents the number of participants who reported a mild or moderate side effect during active tDCS but not sham tDCS.

Time frame:
30 minutes to 1 hour (the period during which the tDCS device was worn) on each of two scan days
Reported as:
Count of participants · Participants
The Percentage of Patients Who Reported a Side Effect in the Active tDCS Condition But Not the Sham tDCS Condition
ParticipantsActive vs Sham Transcranial Direct Current Stimulation During fMRI
The Percentage of Patients Who Reported a Side Effect in the Active tDCS Condition But Not the Sham tDCS Condition3

Adverse events

Collected over 1 day (the day of the scan).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Transcranial Direct Current Stimulation During fMRI0/4 (0%)0/4 (0%)4/4 (100%)
Sham Transcranial Direct Current Stimulation During fMRI0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Most frequent other events
EventActive Transcranial Direct Current Stimulation During fMRISham Transcranial Direct Current Stimulation During fMRI
Scalp burning/itching/tingling sensationNervous system disorders4/43/3
headacheNervous system disorders3/40/3
Sleepiness/dizzinessNervous system disorders3/41/3
Mood change or difficulty concentratingNervous system disorders0/42/3
tension/anxiety/disorientationNervous system disorders2/40/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Both Arms Reported Together.
<=18 years0
Between 18 and 65 years4
>=65 years0
Age, Continuous
Age, Continuous(years)Both Arms Reported Together.
Mean23.5 ± 5.3
Sex: Female, Male
Sex: Female, Male(Participants)Both Arms Reported Together.
Female3
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Both Arms Reported Together.
Hispanic or Latino1
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Both Arms Reported Together.
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race2
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Both Arms Reported Together.
United States4
Quick Inventory Depressive Symptoms
Quick Inventory Depressive Symptoms(units on a scale)Both Arms Reported Together.
Mean11.0 ± 3.6
PROMIS Anxiety Short Form
PROMIS Anxiety Short Form(units on a scale)Both Arms Reported Together.
Mean23.5 ± .6
08

Study locations

1 site
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 24, 2020

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04598152
Lead sponsor
Jay Fournier
Responsible party
Jay Fournier (Assistant Professor of Psychiatry, University of Pittsburgh) — Sponsor-investigator
First posted
Oct 22, 2020
Start date
Oct 1, 2018
Primary completion
Mar 9, 2020
Completion
Mar 9, 2020
Results posted
Jan 4, 2022
Last update
Jan 4, 2022

Study contacts

Jay C Fournier, Ph. D.
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion